OBJECTIVES: CI-994 (N-acetyl dinaline, PD 123654) is a novel oral agent active in a broad variety of murine and human tumor xenografts. While cytotoxic in the Brown Norway (BN) rat leukemia model, growth inhibition in other murine and human tumor xenografts is predominantly cytostatic. Its specific mechanism of action remains unknown. Following CI-994 administration, inhibition of both histone deacetylation and cellular proliferation at the G1 to S transition phase of the cell cycle are observed. This Phase 1 study in patients with solid tumors was carried out to determine a maximum tolerated daily oral dose (MTD) for CI-994 administered on a chronic basis. METHODS: Fifty-three patients received CI-994 daily for treatment durations ranging from 2 to 10 weeks. Dosage escalation proceeded in 2 phases; an Acute Dosing Phase (n = 11) to define the MTD for CI-994 administered over 2 weeks and a Chronic Dosing Phase (n = 29) to define the MTD for daily administration for 8 weeks. Upon completion of the Chronic Dosing Phase, a third cohort of patients (n = 13) received CI-994 at the recommended Phase 2 dose and schedule with 2 additional single doses of drug administered separated by a 1-week washout to assess the effect of food on CI-994 pharmacokinetics. RESULTS: Thrombocytopenia was dose limiting at the MTD of 8 mg/m2/day for 8 weeks. Other toxicities included fatigue and gastrointestinal effects such as nausea, vomiting, diarrhea, constipation and mucositis. Pharmacokinetic studies revealed that peak plasma levels and AUC's generally increased with dose and that food intake did not affect the rate or extent of drug absorption. One patient with heavily pre-treated adenocarcinoma of the lung achieved a Partial Response (PR) lasting over 2 years and 3 additional patients achieved Stable Disease (SD), 1 each with non-small cell lung, colorectal, and renal cancer. CONCLUSIONS: The recommended Phase 2 starting dose is 8 mg/m2/day for 8 weeks repeated after a 2-week drug-free interval.
OBJECTIVES:CI-994 (N-acetyl dinaline, PD 123654) is a novel oral agent active in a broad variety of murine and humantumor xenografts. While cytotoxic in the Brown Norway (BN) ratleukemia model, growth inhibition in other murine and humantumor xenografts is predominantly cytostatic. Its specific mechanism of action remains unknown. Following CI-994 administration, inhibition of both histone deacetylation and cellular proliferation at the G1 to S transition phase of the cell cycle are observed. This Phase 1 study in patients with solid tumors was carried out to determine a maximum tolerated daily oral dose (MTD) for CI-994 administered on a chronic basis. METHODS: Fifty-three patients received CI-994 daily for treatment durations ranging from 2 to 10 weeks. Dosage escalation proceeded in 2 phases; an Acute Dosing Phase (n = 11) to define the MTD for CI-994 administered over 2 weeks and a Chronic Dosing Phase (n = 29) to define the MTD for daily administration for 8 weeks. Upon completion of the Chronic Dosing Phase, a third cohort of patients (n = 13) received CI-994 at the recommended Phase 2 dose and schedule with 2 additional single doses of drug administered separated by a 1-week washout to assess the effect of food on CI-994 pharmacokinetics. RESULTS:Thrombocytopenia was dose limiting at the MTD of 8 mg/m2/day for 8 weeks. Other toxicities included fatigue and gastrointestinal effects such as nausea, vomiting, diarrhea, constipation and mucositis. Pharmacokinetic studies revealed that peak plasma levels and AUC's generally increased with dose and that food intake did not affect the rate or extent of drug absorption. One patient with heavily pre-treated adenocarcinoma of the lung achieved a Partial Response (PR) lasting over 2 years and 3 additional patients achieved Stable Disease (SD), 1 each with non-small cell lung, colorectal, and renal cancer. CONCLUSIONS: The recommended Phase 2 starting dose is 8 mg/m2/day for 8 weeks repeated after a 2-week drug-free interval.
Authors: P M LoRusso; L Demchik; B Foster; J Knight; M C Bissery; L M Polin; W R Leopold; T H Corbett Journal: Invest New Drugs Date: 1996 Impact factor: 3.850
Authors: T H Corbett; B J Roberts; W R Leopold; J C Peckham; L J Wilkoff; D P Griswold; F M Schabel Journal: Cancer Res Date: 1984-02 Impact factor: 12.701
Authors: M R Berger; H Bischoff; E Fritschi; T Henne; M Herrmann; B L Pool; G Satzinger; D Schmähl; U Weiershausen Journal: Cancer Treat Rep Date: 1985-12
Authors: Dikla Engel; Abraham Nudelman; Inesa Levovich; Tal Gruss-Fischer; Michal Entin-Meer; Don R Phillips; Suzanne M Cutts; Ada Rephaeli Journal: J Cancer Res Clin Oncol Date: 2006-07-07 Impact factor: 4.553
Authors: Annemieke J M de Ruijter; Albert H van Gennip; Huib N Caron; Stephan Kemp; André B P van Kuilenburg Journal: Biochem J Date: 2003-03-15 Impact factor: 3.857
Authors: Jürgen Sonnemann; Jennifer Gänge; K Saravana Kumar; Cornelia Müller; Peter Bader; James F Beck Journal: Invest New Drugs Date: 2005-03 Impact factor: 3.850
Authors: Elisabeth I Heath; Patricia M LoRusso; S Percy Ivy; Larry Rubinstein; Michaele C Christian; Lance K Heilbrun Journal: J Biopharm Stat Date: 2009 Impact factor: 1.051
Authors: Guillermo Garcia-Manero; Sarit Assouline; Jorge Cortes; Zeev Estrov; Hagop Kantarjian; Hui Yang; Willie M Newsome; Wilson H Miller; Caroline Rousseau; Ann Kalita; Claire Bonfils; Marja Dubay; Tracy-Ann Patterson; Zuomei Li; Jeffrey M Besterman; Gregory Reid; Eric Laille; Robert E Martell; Mark Minden Journal: Blood Date: 2008-05-21 Impact factor: 22.113